BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

BridgeBio Pharma Inc BBP-418 Update Transcript

Mar 21, 2023 / 12:30PM GMT
Release Date Price: $13.46 (-3.86%)
Operator

Good day, and thank you for standing by. Welcome to today's discussion with BridgeBio, which will cover the company's novel bioassay, updates on Phase II data and the Phase III trial design for BBP-418 in Limb-girdle Muscular Dystrophy Type 2i, known as LGMD2i.

(Operator Instructions) Please be advised that today's conference is being recorded. I would now like to introduce your speakers for today, Dr. Jeffrey Rosenfeld, MD, PhD, a specialist in neuromuscular medicine and Professor of Neurology at Loma Linda University School of Medicine; Dr. Douglas Sproule, CMO of Bridge Bio's LGMD2i program; and Christine Siu, CEO of BridgeBio's LGMD2i program.

I will now hand it over to Neil Kumar, CEO.

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

All right. Thank you, operator, and thanks, everyone, for taking the time to join us this morning. As a brief reminder, and as noted on Slide 2, we will be making forward-looking statements today. Please refer to our filings with the SEC for further information.

All

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot